Racionalʹnaâ Farmakoterapiâ v Kardiologii (Mar 2021)

Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts

  • A. Yu. Lebedeva,
  • O. M. Koteshkova,
  • O. N. Dzhioeva,
  • S. R. Gilyarevsky,
  • T. M. Uskach,
  • M. S. Novikova,
  • Ya. A. Orlova,
  • V. Yu. Kalashnikov,
  • D. V. Privalov,
  • N. A. Ananicheva,
  • M. Yu. Gilyarov,
  • A. D. Erlikh

DOI
https://doi.org/10.20996/1819-6446-2021-01-03
Journal volume & issue
Vol. 17, no. 1
pp. 165 – 168

Abstract

Read online

The results of the international multicenter study EMPEROR-REDUCED were reviewed the on-line scientific meeting of Moscow experts on October 30, 2020. Some proposals and recommendations for further study of the cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with chronic heart failure with reduced ejection fraction were accepted.

Keywords